Lipocine (LPCN) Environmental, Social & Governance (ESG) Data

Company Profile

Search within these filings

View filings

Exhibits within filings

Filing insights

Export filings list

Export a CSV file of filings or unique filing companies (up to first 5,000 results).

Download list of filings Download list of companies

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Environment Environmental Materials Nature Offset Package Packaging Pandemic Regenerative Toxic Wind Access Affordability African American Asian Benefits Black Collective Bargaining Community Culture Customer Cyber Security Data Privacy Death Demographic Demographics Disability Diversity Diversity and Inclusion Drug Pricing Employee Engagement Ethnicity Health and Safety Health Care Healthcare Hiring Hispanic Human Resources Injury Latinx LGBTQ Privacy Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Stakeholder Supplier Supply Chain Talent Training Union Volunteer Women Workforce Assessment Assurance Audit Bonus Chronic Class Action Lawsuit Classified Commitment Controversy Corporate Governance Corporate Purpose Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Independence Independent Innovation Innovative Investigation Lawsuit Lead Independent Director Leadership Litigation Long-term Majority Oversee Oversight Plaintiff Proxy Contest Purpose R&D Reputation Reputational Research and Development Responsibility Responsible Shareholder Proposals Special Meeting Strategy Targets Tax Tenure Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

PX14A6G

LPCN Lipocine Inc

20 May 20

Letter to shareholders

1:08pm

Vote support at last AGM

On June 8, 2022, the Company held its annual general meeting of shareholders, at which time the following items were voted upon:

(1)

Election of Directors. The Company’s shareholders elected for a one-year term six persons nominated for election as directors. The following table sets forth the vote of the shareholders at the meeting with respect to the election of directors:

Nominee	For	Withheld	Broker Non-Vote
Dr. Mahesh V. Patel	39,319,917	4,870,963	18,211,265
Jeffrey A. Fink	38,103,440	6,087,440	18,211,265
John W. Higuchi	38,969,241	5,221,639	18,211,265
Dr. Jill M. Jene	41,726,429	2,464,451	18,211,265
Dr. Richard Dana Ono	38,148,056	6,042,824	18,211,265
Dr. Spyros Papapetropoulos	41,320,732	2,870,148	18,211,265

There were no abstentions with respect to the election of directors.

(2)

Ratification of Appointment of Independent Registered Public Accounting Firm. The Company’s shareholders voted upon and ratified the appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2022. The following table sets forth the vote of the shareholders at the meeting with respect to the appointment of Tanner LLC:

For				Against				Abstain
	60,543,547				1,588,468				270,130

There were no broker non-votes in the ratification of appointment of Tanner LLC as the Company’s independent registered public accountants for the fiscal year ending December 31, 2022.

(3)

Advisory Vote on Executive Compensation. The Company’s shareholders voted upon and adopted a non-binding resolution approving the compensation of the Company’s named executive officers. The following table sets forth the vote of the shareholders at the meeting with respect to the adoption of this resolution on named executive officer compensation:

For				Against				Abstain				Broker Non-Vote
	33,243,925				10,202,014				744,941				18,211,265

(4)

Amendment to the Amended and Restated Certificate of Incorporation of the Company to Increase the Number of Authorized Shares of Common Stock. The Company’s shareholders voted for the proposal to amend the Amended and Restated Certificate of Incorporation of the Company to increase the number of authorized shares of common stock. The following table sets forth the vote of the shareholders at the meeting with respect to this proposal:

For				Against				Abstain
	46,934,209				15,059,865				408,071

(5)

Adjournment of the Annual Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals. The following table sets forth the vote of the shareholders at the meeting with respect adjournment of the Annual Meeting, if necessary:

For				Against				Abstain				Broker Non-Vote
	30,166,003				13,526,986				497,891				18,211,265